This finding is important because it furthers our understanding into the molecular deficits caused by a lack of dystrophin and, if confirmed in human, may provide the basis for the development of new strategies for the pharmacological treatment of DMD cardiomyopathy. This evidence concerns the gene DMD and cardiomyopathy.